revealed that increased expression of plasmacytoma variant translocation 1‐214 transcript (PVT1‐214) is associated with advanced TMN stage, treatment resistance and poor prognosis of CRC. This evidence concerns the gene PVT1 and therapy-related myeloid neoplasm.